Cases: In addition to previously published case reports, further cases of intravascular migration of 31 contraceptive implants have been identified from an information request to two national adverse 32 reaction spontaneous reporting systems. We report on two new cases of insertion into the venous 33 system with subsequent embolism to a pulmonary artery. Conclusion: Incorporating barium sulfate 34 into the implant has facilitated diagnosis of these very rare adverse events with the initial diagnosis 35 of embolism to the pulmonary arterial tree made by chest X-ray. Removal of an implant from a 36 segmental branch of a pulmonary artery is technically challenging and not without risks. 37
Introduction 47
The single-rod etonogestrel implant Implanon was available in the UK between 1999 and 2010. We 48 were aware over this eleven-year period that implants occasionally 'go missing' in the body and 49 cannot be localised [1] . Positive etonogestrel (ENG) blood tests confirmed the presence of the 50 implant but these non-radiopaque implants were difficult to demonstrate using imaging techniques. 51
We could not confirm our suspicions that these implants were located in the lung [2] . However, we 52 felt inadvertent insertion of an implant intravascularly and transit in the venous system to the 53 pulmonary arterial system was possible. One of the authors (DM) has seen two patients in which 54 the key features in the clinical history included painful implant insertion over the area of the sulcus 55 between the biceps and triceps, the site previously recommended by the manufacturers. In both 56
cases there was associated extensive bruising over the upper arm with the distal end of the implant 57 being easy to feel initially and then becoming impalpable. High frequency ultrasound scanning and 58 magnetic resonance imaging of the arm, chest X-rays and computerised tomography scans failed to 59 locate the implants. could not be confirmed to be in the lung by the reporter; the implant appeared to be in the chest 89
wall. There is, thus, a total of two UK cases not previously in the public domain (Cases A and B, Table  90 and limited due to the need for confidentiality to protect individuals' identities. For example we 92
were not permitted access to the women's ages. Also some reports to the regulator contain sparser 93 information. 94
A single case was known to the Irish HPRA and this was confirmed to have already been the subject 95 of a published case report (Case 3, Table 1 clearly on a chest X-ray. 111 112 A major limitation of this case report is the limited information that the MHRA was able to release to 113 us about the two further cases that were reported to them; this was due to strict internal rules 114 about information exchange designed to protect patient and reporter confidentiality. involuntarily infertile. ENG blood levels above 90 pg/mL inhibit ovulation. A US study showed median 142 blood levels of 177 pg/mL (range 68 -471 pg/mL) at four years compared to 189 pg/mL (range 64 -143 803 pg/mL) at three years [11] . We calculate that there would be continued release of ENG from the 144 implant for at least six years if 30 mcg is the average release rate each day. [12] . However, nothing is 145 known about the release characteristics when an implant is located intravascularly rather than its 146 usual subdermal position. In such women artificial reproductive technology may enable ovulation 147 and fertilisation but the endometrium is unlikely to respond favourably to exogenous hormone. 148
We know little about the length of time to diagnosis of intravascular implant embolism in these 149
cases. There may have been a delay, with health care professionals concentrating on imaging the 150 arm to find the implant and then seeking help from tertiary level specialists. Women may then need 151 time to consider whether they undergo a major procedure. The implant in Case 3 had been present 152 for two years and endothelialisation in the artery may have complicated its removal [8] . Case 1 153 presented seven months after insertion and Case 5 ten months after insertion; the latter was 154 removed successfully.
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We know nothing about predisposing factors in these cases. Intuitively this complication would seem 156 more likely to occur when implants are fitted in the sulcus between the biceps and triceps and there 157 is little subcutaneous tissue such as in very thin women. 158
We know nothing about the qualifications or training of the operators who inserted these implants. 159
All we know is that the operator in Case 5 was a general practitioner. It should be noted that the 160 
